Story detail view · 2026-09
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

Quick Summary

A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500